Showing Results for
- Academic Journals (10)
Search Results
- 10
Academic Journals
- 10
- Search Terms:
- 1From: Oncogene. (Vol. 32, Issue 23) Peer-ReviewedAberrant activation of the canonical Wnt signal transduction pathway is involved in many diseases including cancer and is especially implicated in the development and progression of colorectal cancer. The key effector...
- 2From: Oncogene. (Vol. 32, Issue 23) Peer-ReviewedChronic lymphocytic leukemia (CLL) is the most common leukemia in the Western world and remains incurable with conventional chemotherapy treatment approaches. CLL as a disease entity is defined by a relatively...
- 3From: Oncogene. (Vol. 32, Issue 23) Peer-ReviewedTumor necrosis factor related apoptosis-inducing ligand (TRAIL) induces apoptosis specifically in tumor cells and its efficacy has been tested in pre-clinical models by delivering it systemically as a purified ligand or...
- 4From: Oncogene. (Vol. 32, Issue 23) Peer-ReviewedEpigenetic deregulation of gene expression has a role in the initiation and progression of prostate cancer (PCa). The histone methyltransferase MMSET/WHSC1 (Multiple Myeloma SET domain) is overexpressed in a number of...
- 5From: Oncogene. (Vol. 32, Issue 23) Peer-ReviewedDeregulation of microRNA (miRNA) expression can have a critical role in carcinogenesis. Here we show in prostate cancer that miRNA-205 (miR-205) transcription is commonly repressed and the MIR-205 locus is...
- 6From: Oncogene. (Vol. 32, Issue 23) Peer-ReviewedProtein kinase C[alpha] (PKC[alpha]) can phosphorylate the epidermal growth factor receptor (EGFR) at threonine 654 (T654) to inhibit EGFR tyrosine phosphorylation (pY-EGFR) and the associated activation of downstream...
- 7From: Oncogene. (Vol. 32, Issue 23) Peer-ReviewedPancreatic ductal adenocarcinoma (PDAC) is an aggressive neoplastic disease. Gemcitabine, the currently used chemotherapeutic drug for PDAC, elicits only minor benefits, because of the development of escape pathways...
- 8From: Oncogene. (Vol. 32, Issue 23) Peer-ReviewedTumor suppressor p53 is critical for suppressing all types of human cancers, including breast cancer. The p53 gene is somatically mutated in over half of all human cancers. The majority of the p53 mutations are missense...
- 9From: Oncogene. (Vol. 32, Issue 23) Peer-ReviewedMonoclonal antibodies against the epidermal growth factor receptor (EGFR) are effective cancer therapeutics, but tumors harboring RAS mutations are resistant. To functionally dissect RAS-mediated resistance, we have...
- 10From: Oncogene. (Vol. 32, Issue 23) Peer-ReviewedTreatment with histone deacetylase inhibitors (HDACI) results in potent cytotoxicity of a variety of cancer cell types, and these drugs are used clinically to treat hematological tumors. They are known to repress the...